HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120
- 5 July 2012
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (30) , 12111-12116
- https://doi.org/10.1073/pnas.1204533109
Abstract
HIV-1 envelope glycoprotein is the primary target for HIV-1–specific antibodies. The native HIV-1 envelope spike on the virion surface is a trimer, but trimeric gp140 and monomeric gp120 currently are believed to induce comparable immune responses. Indeed, most studies on the immunogenicity of HIV-1 envelope oligomers have revealed only marginal improvement over monomers. We report here that suitably prepared envelope trimers have nearly all the antigenic properties expected for native viral spikes. These stable, rigorously homogenous trimers have antigenic properties markedly different from those of monomeric gp120s derived from the same sequences, and they induce potent neutralizing antibody responses for a cross-clade set of tier 1 and tier 2 viruses with titers substantially higher than those elicited by the corresponding gp120 monomers. These results, which demonstrate that there are relevant immunologic differences between monomers and high-quality envelope trimers, have important implications for HIV-1 vaccine development.Keywords
This publication has 57 references indexed in Scilit:
- Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeysNature, 2012
- Antibody-based protection against HIV infection by vectored immunoprophylaxisNature, 2011
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMCVirology, 2010
- Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodiesNature Structural & Molecular Biology, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Viral membrane fusionNature Structural & Molecular Biology, 2008
- A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodiesProceedings of the National Academy of Sciences, 2008
- Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1Virology, 2007